Zoetis Inc Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)0.82 Intrinsic Value $139.22median of 6 methods · middle span $103-$182based on filings through 30 Jun 2026 Market Price $69.83Price as of 30 Sep 2026 Significantly undervaluedIntrinsic value is 99% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+99%) Data confidence Sign in to view data confidence Market Cap $28.9B Enterprise Value $36.4B Shares Outstanding 417.2M diluted Moat Rating Wide Next Earnings Date5 Nov 2026 Last ex-dividend20 Jul 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Zoetis retains meaningful long-term innovation and diversification strengths, but its near-term earnings profile deteriorated sharply in Q2 2026. U.S. companion-animal sales fell 11%, management cited lower clinic visits, price sensitivity and heightened competition, and full-year organic revenue and adjusted-EPS guidance were reduced materially. International and livestock growth, more than 12 potential blockbuster candidates and continuing product approvals provide recovery optionality, but evidence of U.S. companion-animal stabilization is needed before adopting a more constructive stance. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$80.00 Mean target$100.94 High · most bullish analyst$160.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $80.0020% Lower clinic visits, pet-owner price sensitivity, category competition and generic pressure persist, causing U.S. companion-animal sales and full-year results to fall below the revised guidance floors. Pipeline progress does not offset near-term commercial deterioration. Base CaseCentral scenario $100.9455% Matches the consensus meanZoetis delivers within its revised 2026 revenue and adjusted-EPS ranges, but recovery in U.S. companion animal remains gradual. International and livestock strength partially offset weak domestic companion-animal trends. Bull CaseUpside scenario $160.0025% U.S. companion-animal demand stabilizes, competitive pressure moderates, and international, livestock, diagnostics and recent product launches sustain growth while the pipeline continues delivering significant approvals. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |